Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Pfizer forecast adjusted EPS of $2.80–$3.00 for 2026, below the LSEG analyst consensus of $3.05, and expects revenue of $59.5–$62.5 billion versus estimates of $61.59 billion, noting COVID‑19 product sales will be about $1.5 billion lower than expected in 2025; the stock fell about 0.4% premarket. The guidance highlights ongoing profit pressure from waning COVID demand and may damp investor expectations and valuation near term.

Analysis

Pfizer on Dec. 16 guided 2026 adjusted EPS of $2.80–$3.00, below the LSEG analyst consensus of $3.05, and revenue of $59.5–$62.5 billion versus estimates of $61.59 billion; shares traded down about 0.4% in premarket trading. Management explicitly attributes the shortfall to lower COVID-19 product sales, stating COVID revenue will be roughly $1.5 billion lower than what was expected in 2025, making waning pandemic demand the proximate driver of the guidance miss. The EPS and revenue ranges therefore create a direct downside revision to 2026 expectations and set a lower baseline for analyst models.

The market reaction has been muted but sentiment signals are mildly negative, indicating investors view the miss as material but not crisis-level; this typically precedes analyst model updates and potential rating changes. The primary implication for company fundamentals is near-term profit pressure tied to COVID product volume rather than an operational restructuring disclosed in the article. Key information flow to watch will be actual COVID product sales figures in upcoming reports and any explicit management plans to offset the revenue gap.

The guidance miss increases the probability of incremental volatility around quarterly results and analyst revisions; given the 0.4% move and sentiment score, the market may reprice PFE incrementally rather than sharply absent other negative news. Investors should treat this as a directional signal that profitability for 2026 will be below prior consensus until new information arrives.

Key Decisions for Investors

• Consider trimming or hedging near-term exposure to PFE given guidance below consensus and the identified $1.5 billion COVID revenue shortfall, especially ahead of subsequent quarterly updates
• Monitor reported COVID-19 product sales and the next quarterly guidance closely as the primary driver of 2026 earnings risk and be prepared for analyst model revisions
• If maintaining a long-term position, wait for clearer management mitigation plans or analyst revisions before adding materially, and use any deeper, evidence-backed pullback as a disciplined entry opportunity